BCYC
Bicycle TherapeuticsBCYC
BCYC
About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Employees: 305
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
2.96% more ownership
Funds ownership: 85.14% [Q3] → 88.1% (+2.96%) [Q4]
8% less funds holding
Funds holding: 105 [Q3] → 97 (-8) [Q4]
17% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 35
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
30% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 23
36% less capital invested
Capital invested by funds: $915M [Q3] → $586M (-$329M) [Q4]
42% less call options, than puts
Call options by funds: $148K | Put options by funds: $256K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
182%
upside
Avg. target
$30
221%
upside
High target
$33
258%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia 13% 1-year accuracy 22 / 164 met price target | 225%upside $30 | Buy Reiterated | 9 Apr 2025 |
Citizens Capital Markets Reni Benjamin 15% 1-year accuracy 6 / 40 met price target | 182%upside $26 | Market Outperform Reiterated | 26 Feb 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 21% 1-year accuracy 40 / 192 met price target | 258%upside $33 | Buy Reiterated | 26 Feb 2025 |
Financial journalist opinion
Based on 4 articles about BCYC published over the past 30 days
Neutral
Seeking Alpha
1 day ago
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.
Neutral
Business Wire
3 weeks ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Neutral
Business Wire
3 weeks ago
Bicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, at 12:45 p.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the company's we.
Neutral
Business Wire
3 weeks ago
Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced several new governance and key clinical leadership appointments. Felix J. Baker, Ph.D., will succeed Pierre Legault, BAA, MBA, CPA, CA, as chairman of the Bicycle Therapeutics Board of Directors as Mr. Legault and Richard Kender, MBA, will retire f.
Neutral
Business Wire
1 month ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on March 3, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 73,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Neutral
Business Wire
1 month ago
Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate updates. “In 2024, the significant progress across our pipeline and business continued to validate our approach to developing next-generati.
Neutral
Business Wire
2 months ago
Bicycle Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that management will participate in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on Wednesday, Feb. 12, at 10 a.m. ET. A live webcast of the fireside chat will be accessible from the Investor section of the com.
Neutral
Business Wire
2 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on February 3, 2025, the Compensation Committee of the company's Board of Directors granted to 18 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 117,300 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Neutral
Seeking Alpha
2 months ago
Bicycle Therapeutics: Trading At Cash, Underwhelming But Not Unsalvageable Data
Bicycle Therapeutics' BT8009 showed promising efficacy and safety in early trials, but mixed results in combination with Keytruda caused significant stock volatility. BT8009 demonstrated a superior safety profile compared to PADCEV, with fewer and milder adverse events due to its shorter half-life and faster elimination. Financially, BCYC is solid with $890 million in cash, providing a runway of 11-12 quarters, though it trades at cash value.
Neutral
Business Wire
3 months ago
Bicycle Therapeutics Announces Updated Topline Zelenectide Pevedotin Data and Highlights 2025 Strategic Priorities and Milestones
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab in previously untreated (first-line) cisplatin-ineligible patients with metastatic urothelial cancer (mUC). The company also announced recent accomplishments and.
Charts implemented using Lightweight Charts™